Information LIT-927 is a novel neutraligand ofCXCL12with Ki value of 267 nM for inhibition of Texas red-labeled CXCL12 (CXCL12-TR) binding. It shows high selectivity toward CXCL12 vs other chemokines also involved in asthma. Targets CXCR4 ; CXCL12 ; 267 nM(Ki) In vitro LIT-927 is able to bind selectively CXCL12 and to inhibit CXCL12-CXCR4 interaction. In vivo In a murine model of hypereosinophilia, LIT-927 shows a large and statistically reliable inhibition of eosinophil recruitment. It inhibits allergic eosinophilic airway inflammation in mice when administered orally or locally.